Doxorubicin Resistance in Lung Cancer Cells
Author Information
Author(s): P. Nygren, R. Larsson, A. Gruber, C. Peterson, J. Bergh
Primary Institution: University Hospital, University of Uppsala
Hypothesis
Does the development of resistance to doxorubicin in small cell lung cancer cells also confer resistance to other cytotoxic drugs and involve changes in drug accumulation and P-glycoprotein expression?
Conclusion
The study found that doxorubicin resistance in small cell lung cancer cells is characterized by atypical multidrug resistance mechanisms, including the absence of P-glycoprotein overexpression.
Supporting Evidence
- Resistance to doxorubicin was accompanied by cross-resistance to vincristine and other drugs.
- Verapamil was able to reverse doxorubicin resistance in some cell lines.
- Calcium levels were found to be elevated in resistant cell lines.
Takeaway
Some lung cancer cells can become resistant to a drug called doxorubicin, and this resistance can also make them resistant to other drugs, but it doesn't always happen in the usual way.
Methodology
The study involved culturing small cell lung cancer cell lines in the presence of doxorubicin and assessing their resistance to various drugs, as well as measuring cytoplasmic calcium levels and P-glycoprotein expression.
Limitations
The study primarily focused on in vitro cell lines, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website